| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 86 | 11.8x | 17.3x | Top tier | |
Growth | 55 | 20.6% | 7.1% | Around median | |
Quality | 78 | 7.3% | 4.5% | Top tier | |
Safety | 78 | 1.2x | 2.6x | Top tier | |
Capital Return | 77 | 10.71% | 0.06% | Top tier | |
Momentum | 34 | -18.1% | -1.6% | Bottom tier | |
Sentiment | 89 | 7 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Sanofi is a biopharmaceutical company whose revenue depends on specialty medicines and vaccines, with a clear focus on immunology, rare diseases, hematology, and oncology. Dupixent leads the portfolio, generating €15.7 billion in fiscal 2025, while vaccine sales reached €7.9 billion and sales of newly launched medicines and vaccines reached €5.7 billion. Other drivers included Beyfortus with sales of €1.8 billion and ALTUVIIIO with sales of €1.2 billion, alongside the launches of Qfitlia, Wayrilz, and Nuvaxovid.
In fiscal Q2 2026, Sanofi reported revenue of $12.3 billion and gross profit of $9.3 billion, equivalent to a gross margin of approximately 75.6%. Net income was $343 million, or about 2.8% of revenue, and earnings per share were $0.14. Compared with fiscal Q1 2026, revenue increased from $11.2 billion, but net income declined from $1.6 billion and earnings per share from $0.67.
For fiscal 2025, financial statement data showed revenue of $46.7 billion, gross profit of $33.7 billion, and net income of $7.9 billion. According to the operating figures presented by management in euros, sales reached €43.6 billion and grew 9.9% at constant exchange rates, the business gross margin expanded by 1.8 percentage points to 77.5%, while the business operating income margin reached 27.8%. The company also generated free cash flow of €8.1 billion, equivalent to 18.5% of sales.
The average analyst price target is $49.5, within a very narrow range between $49 and $50, compared with a consensus rating of Neutral. This average is below the 52-week high of $52.68 and above the low of $40.89; the valuation reflects a balance between the increase in the fiscal 2026 growth outlook to approximately 10% and weak fiscal Q2 2026 net income and certain research pipeline setbacks, with no valid price-to-earnings ratio available in the data.
Figures in the text are as of 2026-08-26; the live price is shown at the top of the page.
Dupixent is the largest driver, generating sales of €15.7 billion in fiscal 2025, including €4.2 billion in fiscal Q4 2025. The drug expanded into chronic obstructive pulmonary disease, chronic spontaneous urticaria, and bullous pemphigoid, and patient numbers increased by more than 30% during fiscal 2025. According to management, Dupixent remained the most prescribed biologic across dermatology, pulmonology, allergy, and ear, nose, and throat specialties.
Revenue reached $12.3 billion and gross profit reached $9.3 billion in fiscal Q2 2026, equivalent to a gross margin of approximately 75.6%. Net income was $343 million and earnings per share were $0.14, compared with $1.6 billion and $0.67 in fiscal Q1 2026. On August 5, 2026, news coverage described the results as below analyst expectations.
On July 30, 2026, Sanofi raised its outlook to approximately 10% sales growth in fiscal 2026, with core earnings per share growing faster than sales. The January 29, 2026 guidance targeted high-single-digit sales growth and slightly faster growth in business earnings per share before the subsequent update. This compares with operating sales growth of 9.9% at constant exchange rates in fiscal 2025.
Automated analysis for informational purposes only — not investment advice.
Beyfortus generated sales of €1.8 billion in fiscal 2025, up 9.5%, and became available in more than 45 countries. Sanofi said it protected more than 11 million infants and helped prevent an estimated 200 thousand hospital admissions, with real-world effectiveness between 87% and 98%. ALTUVIIIO generated sales of €1.2 billion in fiscal 2025, reaching blockbuster status.
During fiscal 2025, Sanofi recorded twelve Phase 3 readouts and fifteen Phase 2 readouts and added ten molecules to Phase 1, including three gene therapies. Identified catalysts for the second half of 2026 include AQUA and ESTUARY results for amlitelimab, in addition to data for lunsekimig and venglustat. Conversely, the PERSEUS study of tolebrutinib failed to meet its primary endpoint, and the company will not pursue a regulatory submission for the treatment of primary progressive multiple sclerosis.
The analyst consensus rates SNY as Neutral, with an average price target of $49.5. Targets range only between $49 and $50, which is a narrow range, while the 52-week range is between $40.89 and $52.68. The data does not provide a valid price-to-earnings ratio, so the valuation assessment is based on analyst targets and the strength of Dupixent's growth versus weak fiscal Q2 2026 earnings and research pipeline risks.